KRIVA is an enhanced reformulation of the approved drug rivaroxaban (Xarelto®), which has significant potential as a novel treatment in Antiphospholipid Syndrome (APS). APS is a rare blood disorder characterized by frequent clotting which creates significant issues that worsen with age and can be life-threatening. Currently, warfarin is used as an off-label treatment but presents many safety and convenience challenges to patients. Xarelto failed in Phase II for this indication and there are no approved drugs indicated for APS. KRIVA displays enhanced absorption which may allow efficacious, safe, higher dosing for tens of thousands of patients needing a better treatment option. KRIVA could potentially be the first approved product for APS.